Clinical decision making in castration-resistant prostate cancer according to baseline prostate-specific antigen: are we measuring disease burden or disease biology?
- PMID: 25220371
- DOI: 10.1016/j.eururo.2014.08.069
Clinical decision making in castration-resistant prostate cancer according to baseline prostate-specific antigen: are we measuring disease burden or disease biology?
Comment on
-
Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.Eur Urol. 2015 Feb;67(2):223-30. doi: 10.1016/j.eururo.2014.08.025. Epub 2014 Aug 27. Eur Urol. 2015. PMID: 25171902 Clinical Trial.